GlassScriptPhysician profile
Anuradha Ranganath
NPI 1881046050
$2,341.79
in general payments reported to CMS, 2019-2025
23 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.55 · 2020: $24.87 · 2021: $354 · 2022: $376 · 2023: $526 · 2024: $591 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.27 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $398.84 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $231.26 | 2021-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $196.45 | 2021-2023 | Camzyos, Eliquis |
| Abbvie INC. | $178.39 | 2025 | |
| Glaxosmithkline, LLC. | $133.30 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Dexcom, INC. | $83.28 | 2021-2022 | |
| Pfizer INC. | $82.59 | 2021-2025 | |
| Amgen INC. | $59.73 | 2020-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $56.01 | 2022-2023 | |
| Exact Sciences Corporation | $49.45 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $40.01 | 2021 | |
| Sanofi Pasteur INC. | $39.49 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.07 | 2023 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.63 | 2023 | Hyqvia |
| Metacel Pharmaceuticals LLC | $21.16 | 2024 | Ozobax |
| Verona Pharma, INC. | $20.84 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $18.96 | 2021 | |
| Abbott Laboratories | $18.35 | 2021 | |
| Alkermes, INC. | $18.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Ranganath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.